NDAORALTABLET
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
MYFEMBREE (relugolix, estradiol hemihydrate, and norethindrone acetate) by Sumitomo Dainippon Pharma is gonadotropin releasing hormone receptor antagonists [moa]. First approved in 2021.
Drug data last refreshed 2h ago · AI intelligence enriched 5h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYFEMBREE is an oral combination tablet containing relugolix (a GnRH receptor antagonist), estradiol hemihydrate, and norethindrone acetate approved in May 2021. It works by blocking gonadotropin-releasing hormone signaling to suppress ovarian function, addressing hormonal imbalances in women. The fixed-dose combination provides both hormonal suppression and estrogen-progestin replacement in a single daily tablet.
$0.002BPart D
Peak16.4 years to LOEEarly-stage product in peak adoption phase with modest Part D claims suggesting niche market penetration; commercial teams focused on specialist awareness and patient access rather than large-scale infrastructure.
Mechanism of Action
Gonadotropin Releasing Hormone Receptor Antagonists
Pharmacologic Class:
Gonadotropin Releasing Hormone Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MYFEMBREE represents a specialized career opportunity within women's health and gynecology-focused organizations; roles emphasize specialist engagement and niche market penetration rather than mass-market launch infrastructure. Early commercial adoption and extended patent protection offer moderate stability for mid-career professionals seeking focused therapeutic expertise.
Brand Manager
Worked on MYFEMBREE at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.